Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 12:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Sickle Cell Disease, Thalassemia
Interventions: Hydroxyurea, Hydroxyurea Oral Capsule; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 9 Months to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Cognitive Change
Interventions: Drink; Dietary Supplement
Lead sponsor: University of Memphis; Other
Eligibility: 40 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Dry Eye Syndromes
Interventions: cyclosporine ophthalmic emulsion Formulation A, cyclosporine ophthalmic emulsion Formulation B, cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%, cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%, cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Comparison of 2 Different Formulations of 12 mg Proellex Vaginal Capsules
Interventions: Proellex Formulation A, Proellex Formulation B; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 47 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV (GSK3389245A) low dose formulation vaccine, RSV (GSK3389245A) middle dose formulation vaccine, RSV (GSK3389245A) high dose formulation vaccine, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 23 Months
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Anaheim, California • Aurora, Colorado • Topeka, Kansas + 3 more

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: LGD-6972 Solution, LGD-6972 Capsules; Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cervical Dystonia
Interventions: botulinum toxin type A, botulinum toxin type A Formulation 2, Normal Saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Ulcerative Colitis
Interventions: ALTB-268; Biological
Lead sponsor: AltruBio Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 23
States / cities: San Diego, California • Littleton, Colorado • Miami, Florida + 20 more

Conditions: GIST
Interventions: Inlexisertib, Ripretinib; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 11
States / cities: Los Angeles, California • Miami, Florida • Worcester, Massachusetts + 7 more

Conditions: Skin Ageing, Facial Wrinkles, Acne, Skin Elasticity, Infraorbital Dark Circle Severity, Skin Firmness, UV Spots, Skin Texture, Skin Pores, Brown Spots, Porphyrins, Red Spots
Interventions: NIRA Laser M2.1, Topical; Device · Other
Lead sponsor: NIRA Innovations Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Beverly, Massachusetts

Conditions: Dialysis, Anemia
Interventions: Roxadustat, Oral Iron, IV Iron; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Northridge, California • Yuba City, California • Detroit, Michigan

Conditions: Healthy
Interventions: ALXN1840 Enteric-coated Tablet, ALXN1840 Non-coated Capsule, Omeprazole; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir, Lamivudine, Dolutegravir + Lamivudine FDC Formulation 1, Dolutegravir + Lamivudine FDC Formulation 2; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Psoriasis
Interventions: U0267, Vehicle; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 12 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 13
States / cities: San Diego, California • Denver, Colorado • Miami, Florida + 9 more

Conditions: Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions: Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN); Device · Drug
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: New York, New York

Conditions: Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
Interventions: bremelanotide; Drug
Lead sponsor: Palatin Technologies, Inc; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 65
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 60 more

Conditions: Healthy
Interventions: JNJ-56021927 capsule, JNJ-56021927 tablet; Drug
Lead sponsor: Aragon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Alzheimer's Disease, Huntington Disease
Interventions: Dimebon IR Tablet, Dimebon MR1, Dimebon MR2, Dimebon MR3, Dimebon MR4; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Benazepril HCl 40 mg Tablets, Lotensin® 40 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy Volunteers
Interventions: CB-839 Capsules, CB-839 Tablets; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Soft Tissue Sarcoma
Interventions: Trabectedin; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 90 Years
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cocaine Use Disorder
Interventions: Original formulation EMB-001, New formulation EMB-001; Drug
Lead sponsor: Embera NeuroTherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Herpes Simplex
Interventions: Famciclovir; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 12 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 11
States / cities: Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 8 more

Conditions: Herpes Simplex Virus Keratitis
Interventions: oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily, oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere

Effect of Alpha Hope Dietary Supplement on Health and Cognitive Performance

Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye

Comparison of Two Formulations of Proellex for Vaginal Administration

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia

Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Clinical Study Evaluating the Safety and Effectiveness of the NIRA Laser M2.1 for the Treatment of Full-Face Wrinkles

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants

A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)

Benazepril HCl 40 mg Tablets, Fasting

A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults

YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access

Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations

Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection

Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis